Form 4: Coeptis Director DeSilva Boosts Stake via Options, Restricted Stock

Coeptis Therapeutics Director Tara DeSilva increased her direct beneficial ownership of common stock through option exercise and a restricted stock grant.

Summary

• Tara DeSilva, a Director of Coeptis Therapeutics Holdings, Inc. (COEP), reported changes in her beneficial ownership of common stock.
• On February 11, 2026, DeSilva acquired 5,700 shares of common stock by exercising stock options at a price of $10.56 per share.
• On the same date, she also received a grant of 3,250 shares of restricted stock at a price of $0, as part of an option exchange program where she surrendered previously held underwater options.
• Following these transactions, DeSilva directly beneficially owns a total of 8,950 shares of Coeptis Therapeutics common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive, as a director increasing their stake generally signals confidence, though the context of an option exchange for underwater options introduces a nuanced perspective on past performance.

Positives

• Director Tara DeSilva increased her direct beneficial ownership in Coeptis Therapeutics by 8,950 shares, signaling confidence in the company's future.
• The exercise of stock options at $10.56 per share indicates a belief in the company's value above this price.
• The option exchange program allowed the Director to convert underwater options into restricted stock, potentially re-aligning incentives more effectively with current company valuation.

Negatives

• The grant of restricted stock at $0 per share, while part of an option exchange, contributes to dilution for existing shareholders.
• The surrender of 'underwater options' suggests that previous option grants were out-of-the-money, indicating past stock price underperformance relative to the strike price.

Risks

• The existence of 'underwater options' prior to the exchange program suggests potential past stock price underperformance, which could recur.
• Equity compensation, particularly restricted stock grants, can lead to dilution for existing shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider buying, especially by directors, can be viewed positively as it signals confidence in the company's future prospects. However, the context of an option exchange program for underwater options suggests past challenges in stock performance.

Corporate Governance

Related Party Transactions

• Exercise of stock options by Director Tara DeSilva to acquire 5,700 shares of common stock at $10.56 per share.
• Grant of 3,250 shares of restricted stock to Director Tara DeSilva at $0 per share, in exchange for previously held underwater options.

Stakeholder Impact

• Shareholders: Increased insider ownership could be seen as a positive signal of confidence. However, the restricted stock grant at $0 and the underlying 'underwater options' suggest potential past dilution or underperformance.
• Employees: The option exchange program might be part of a broader compensation strategy, potentially impacting employee morale if similar programs are offered.

Key Dates

Keywords

Coeptis Therapeutics, COEP, Tara DeSilva, Form 4, insider trading, stock options, restricted stock, director ownership, equity compensation